Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care
Mandate

Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care

August 26, 2010

Vinge is advising Investor AB (publ) in connection with Investor’s agreement with Morgan Stanley Principal Investments to acquire Morgan Stanley’s 34 per cent equity stake in Mölnlycke Health Care Group AB. The purchase price amounts to EUR 510 million and following the transaction Investor will hold a 96 per cent equity stake. The remaining shares will be owned by Mölnlycke’s management and board.

Mölnlycke is a world leading manufacturer and provider of single-use surgical and wound care products and services, primarily for the professional healthcare sector. Investor together with Morgan Stanley originally invested in Mölnlycke in 2007.

Vinge’s team advising Investor consists of Ola Sandersson, Pontus Enquist, Dain Nevonen and Fredrik von der Esch. Johan Karlsson and Peter Alstegren are providing competiton law advice. Hans Wibom is the client relationship partner.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025